HOME   |    PDF   |   


Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management



Sambit Das1, A K Gupta2, Biplab Bandhopa3, B Harish Darla4, Vivek Arya5, Mahesh Abhyankar6,*, Santosh Revankar6



1Endeavour Clinics, Bhubaneswar, India; 2Rahas Medical Store Hospital, Lucknow, India; 3Thyroid, Diabetes & Hormone Care, Indore, India; 4Darla's Healthcare, Mysore, India; 5Center for Endocrine and Diabetes, Ahmedabad, India; 6USV Pvt. Ltd., Mumbai, India



Dr. Mahesh Abhyankar Email: dr.mabhyankar@gmail.com


Article Type

Research Article



Received February 28, 2021; Revised March 15, 2021; Accepted March 18, 2021, Published March 31, 2021



It is of interest to evaluate the clinical effectiveness and safety of vildagliptin as monotherapy and combination therapy of vildagliptin and metformin for the management of type 2 diabetes mellitus (T2DM) patients in Indian settings. The study included patients with T2DM (aged >18 years) receiving vildagliptin monotherapy and vildagliptin in combination with metformin therapy of various strengths. Data related to demographics, risk factors, medical history, glycated hemoglobin (HbA1c) levels, and medical therapies were retrieved from medical records. Out of 9678 patients (median age, 52.0 years), 59.1% were men. A combination of vildagliptin and metformin (50/500 mg) was the most commonly used therapy (54.8%), and the median duration of therapy was 24.0 months. The predominant reason for selecting vildagliptin therapy was to improve HbA1c levels (87.8%). A total of 87.5% of patients required dosage up-titration. Vildagliptin therapy was used in patients with T2DM and associated complications (peripheral neuropathy, CAD, nephropathy, retinopathy, autonomous neuropathy, stroke/TIA, and peripheral artery disease). Among 5175 patients who experienced body weight changes, a majority of patients had lost weight (68.6%). The target glycemic control was achieved in 95.3% of patients. The mean HbA1c levels were significantly decreased post-treatment (mean change: 1.34%; p<0.001). Adverse events were reported in 0.4% of patients. Physicians rated the majority of patients as good to excellent on the global evaluation of efficacy and tolerability scale (98.9%, each). Vildagliptin with or without metformin was an effective therapy in reducing HbA1c helps in achieving target glycemic control, and was well-tolerated in Indian patients with T2DM continuum.



Antidiabetic therapy, DPP4i, glycemic control, hypertension.



Das et al. Bioinformation 17(3): 413-423 (2021)


Edited by

P Kangueane






Biomedical Informatics



This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.